Novartis introduces new U.S. website for Denagard® (tiamulin hydrogen fumarate)

Novartis Animal Health has created a new U.S. website exclusively for Denagard^® (tiamulin hydrogen fumarate), a highly effective antibiotic for therapeutic treatment of common swine bacterial diseases impacting U.S. pork production operations.

The new website, www.us.denagard.com, provides a wealth of information designed to help producers reduce the risk of enteric and respiratory diseases through prevention practices and properly timed therapeutic treatment.

“The design of this new website combines a fresh look and valuable information in an easy to access format,” said Doug Sullivan, Marketing Manager, Swine and Poultry, Novartis Animal Health. “We strive to make it easy for producers and veterinarians to interact with and conduct business with Novartis and hope this site reflects that approach.”

Health management strategies for controlling disease in both nursery and grow-finish pigs are included on the website. In addition to disease information, prevention strategies and administration guidelines, the website also offers an email alert sign-up and quick access to app downloads.

“We’re very pleased to offer this Denagard website as a convenient resource for producers, veterinarians and other industry professionals,” said Mark Hammer, DVM, professional services veterinarian, Novartis Animal Health.

“In addition to recommendations for controlling ileitis, swine dysentery, swine pneumonia and other diseases, we have included many of the most recent research papers and university diagnostic data. The swine health challenges facing U.S. producers are constantly evolving. The new Denagard website will be an excellent resource for health management topics.”

Denagard Premix has a proven track record of efficacy and reliability. It can be used alone to control key enteric diseases, including ileitis and swine dysentery. Denagard Premix can also be used concurrently with chlortetracycline (CTC) to provide enteric and respiratory disease treatment, respectively.

Denagard Liquid Concentrate (LC) is the only water-based formulation that treats both swine dysentery and swine pneumonia. Its unique formulation allows pigs to quickly and conveniently receive needed medication, even if they’ve gone off feed.

To learn more about Denagard and swine health management tips that drive maximum performance, visit www.us.denagard.com or contact your Novartis Animal Health representative.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as “will,” or similar expressions, or by express or implied discussions regarding potential future revenues from Denagard. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Denagard to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Denagard will achieve any particular levels of revenue in the future. In particular, management’s expectations regarding Denagard could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; the impact that the foregoing factors could have on the values attributed to the Novartis Group’s assets and liabilities as recorded in the Group’s consolidated balance sheet, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Animal Health US, Inc.

Headquartered in Greensboro, NC, Novartis Animal Health US, Inc. researches, develops and commercializes leading animal treatments that meet the needs of pet owners, farmers and veterinarians. Part of the Basel, Switzerland-based Novartis Animal Health global organization, the US business is the largest of the 40 countries where Novartis Animal Health operates.  For more information about Novartis Animal Health US, Inc., please consult http://www.ah.novartis.us.